Clinical Trial

Neo Adjuvant Chemotherapy in Triple Negative Breast Cancer

Study acronym: neo-TN
Active, Not Recruiting Phase 2/3
View on ClinicalTrials.gov →
Record status
This record was last updated October 12, 2022 (before its estimated June 2023 completion). Its status may not reflect the trial's current state.
Summary
This study aims to compare the response of triple-negative breast cancer with deficient homologous recombination to intensified alkylating chemotherapy versus standard chemotherapy with dose dense AC and/or Docetaxel-Capecitabine.
Protocol Amendment History 14 amendments
This ClinicalTrials.gov record has been amended 14 times since 2010-01-26; most recent amendment 2022-10-11.
Status change: Recruiting → Active, Not Recruiting 2016-03-30
Trial Details
NCT Number NCT01057069
Lead Sponsor The Netherlands Cancer Institute
Conditions Breast Cancer
Enrollment 310 participants
Start Date 2010-01
Primary Completion 2023-06 (estimated)
Study Completion 2029-12 (estimated)
Updated on ClinicalTrials.gov 2022-10-12